Everything below concerns visceral adiposity. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-26. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
=== Adobe ColdFusion (2016 Release) === Adobe ColdFusion (2016 release), known generically as ColdFusion 2016 was released on February 16, 2016. During development, it was codenamed Raijin. New or improved features available in all editions (Standard, Enterprise, and Developer) include:
Molecular glues that target BRD4 for degradation, lead to 26S proteasome generated peptides that release Inhibitor of apoptosis (IAPs) leading to Apoptosis, suggesting that the peptides generated by the 26S act as secondary metabolites that drive major cell processes.
More than 40 years of activity provided Rush with the opportunity for musical diversity across their discography. As with many bands known for experimentation, changes inevitably resulted in dissent among critics and fans. The bulk of the band's music included synthetic instruments and this has been a source of contention among fans and critics, especially the band's heavy usage of synthesizers and keyboards during the 1980s, particularly on Grace Under Pressure, Power Windows, and Hold Your Fire. The members of Rush have noted that people "either love Rush or hate Rush", resulting in strong detractors and an intensely loyal fan base. In 1979, The Rolling Stone Record Guide called them "the power boogie band for the 16 magazine graduating class". A July 2008 Rolling Stone article said, "Rush fans are the Trekkies/trekkers of rock". Rush have been cited as an influence or inspiration by artists including Alice in Chains, Anthrax, Celtic Frost, the Cro-Mags, Dream Theater, Exodus, Exciter, Fates Warning, Fishbone, Foo Fighters, Iron Maiden, Jane's Addiction, King's X, Living Colour, Manic Street Preachers, Mastodon, Megadeth, Meshuggah, Metallica, No Doubt, Pearl Jam, the Pixies, Primus, Queensrÿche, Rage Against the Machine, the Red Hot Chili Peppers, Sepultura, Slayer, the Smashing Pumpkins, Elliott Smith, Soundgarden, Stone Temple Pilots, System of a Down, Testament, Tool, Venom, Voivod, and Steven Wilson.
Sources: en.wikipedia.org
Bavington, Dean L. Y. Managed Annihilation: An Unnatural History of the Newfoundland Cod Collapse (University of British Columbia Press; 2010) 224 pages. Links the collapse of Newfoundland and Labrador cod fishing to state management of the resource. Cobb, John N. (1916). Pacific Cod Fisheries. Bureau of Fisheries Document. Vol. 830. Washington, DC: Government Printing Office. OCLC 14263968. Greenberg, Paul (2010). Four Fish: The Future of the Last Wild Food. New York: Penguin Press. ISBN 978-1-59420-256-8. OCLC 813929026. Mark Kurlansky (1997). Cod: A Biography of the Fish That Changed the World. Shields, Edward (2001). Salt of the Sea: The Pacific Coast Cod Fishery and the Last Days of Sail. Lopez Island, Wash.: Heritage House. ISBN 978-1-894384-35-3.
== Further reading == Perkins, D. H. (1984-12-01). "Proton Decay Experiments". Annual Review of Nuclear and Particle Science. 34 (1): 1–50. Bibcode:1984ARNPS..34....1P. doi:10.1146/annurev.ns.34.120184.000245. ISSN 0163-8998. Luciano Maiani (8 February 2006). The problem of proton decay (PDF). Third NO-VE International Workshop on Neutrino Oscillations in Venice. Venice. Nath, Pran; Fileviez Pérez, Pavel (April 2007). "Proton stability in grand unified theories, in strings and in branes". Physics Reports. 441 (5–6): 191–317. arXiv:hep-ph/0601023. Bibcode:2007PhR...441..191N. doi:10.1016/j.physrep.2007.02.010. S2CID 119542637. Dev, P. S. B.; et al. (2022-09-26), "Searches for Baryon Number Violation in Neutrino Experiments: A White Paper", Journal of Physics G: Nuclear Physics, 51 (3): 033001, arXiv:2203.08771, Bibcode:2024JPhG...51c3001D, doi:10.1088/1361-6471/ad1658
In the large intestine the passage of the digesting food in the colon is a lot slower, taking from 30 to 40 hours until it is removed by defecation. The colon mainly serves as a site for the fermentation of digestible matter by the gut flora. The time taken varies considerably between individuals. The remaining semi-solid waste is termed feces and is removed by the coordinated contractions of the intestinal walls, termed peristalsis, which propels the excreta forward to reach the rectum and exit through the anus via defecation. The wall has an outer layer of longitudinal muscles, the taeniae coli, and an inner layer of circular muscles. The circular muscle keeps the material moving forward and also prevents any back flow of waste. Also of help in the action of peristalsis is the basal electrical rhythm that determines the frequency of contractions. The taeniae coli can be seen and are responsible for the bulges (haustra) present in the colon. Most parts of the GI tract are covered with serous membranes and have a mesentery. Other more muscular parts are lined with adventitia.
Sources: en.wikipedia.org
== Adverse effects == Cefodizime has been shown to be generally well tolerated in drug trials and its adverse effects are mainly gastrointestinal or dermatological. Gastrointestinal adverse effects were observed in 2.4% of patients during clinical trials and included: diarrhea, nausea, vomiting, and elevated transaminases. Allergic symptoms were observed in 1.1% of patients and include: exanthema, urticaria, and pruritus. Other adverse effects observed include local site reactions, pain at site of injection, and phlebitis.
Inspired by Michael Abrash, who left Microsoft to work on the game Quake at id, Newell and another employee, Mike Harrington, left Microsoft to found the video game company Valve on August 24, 1996. Newell opted to found Valve instead of retiring as he felt working with "other really smart, motivated, socially orientated people to create product that would affect millions of other people" would be more fun. Newell and Harrington funded development of the first Valve game, the first-person shooter Half-Life (1998), which was a critical and commercial success. Harrington sold his stake in Valve to Newell in 2000. Newell gave Valve no deadline and a "virtually unlimited" budget to develop Half-Life 2 (2004), promising to fund it himself if necessary. He and Valve came close to bankruptcy during a legal battle with Vivendi Games, which ended when an intern discovered an email revealing that Vivendi was destroying evidence.
=== Metabolic niche partitioning === In 2010, exometabolomics analysis of the cyanobacterium, Synechococcus sp. PCC 7002 by Baran, et al. revealed that this photoautotroph could deplete a diverse pool of exogenous metabolites. A follow-up exometabolomics study on sympatric microbial isolates from biological soil crust, which exist in communities with cyanobacteria in the desert soils of the Colorado Plateau, suggested that metabolite niche partitioning exists in these communities, where each isolate only utilizes 13-26% of metabolites from the soil
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.